Entities Quality Rankings

Migration, Crosslink

📖

Entities Quality Rankings

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-quality-rankings

📖 Wiki Page

entity1684 wordssynced 2026-04-02

Overview

flowchart TD entities_quality_rankings["Entities Quality Rankings"] style entities_quality_rankings fill:#4fc3f7,stroke:#333,color:#000 entities_quality_ran_0["Quality Scoring Methodology"] entities_quality_rankings -->|"includes"| entities_quality_ran_0 style entities_quality_ran_0 fill:#81c784,stroke:#333,color:#000 entities_quality_ran_1["Scoring Dimensions"] entities_quality_rankings -->|"includes"| entities_quality_ran_1 style entities_quality_ran_1 fill:#ef5350,stroke:#333,color:#000 entities_quality_ran_2["Score Interpretation"] entities_quality_rankings -->|"includes"| entities_quality_ran_2 style entities_quality_ran_2 fill:#ffd54f,stroke:#333,color:#000 entities_quality_ran_3["Top 10 Highest Quality Pages"] entities_quality_rankings -->|"includes"| entities_quality_ran_3 style entities_quality_ran_3 fill:#ce93d8,stroke:#333,color:#000 entities_quality_ran_4["Characteristics of High-Quality Pages"] entities_quality_rankings -->|"includes"| entities_quality_ran_4 style entities_quality_ran_4 fill:#4fc3f7,stroke:#333,color:#000 entities_quality_ran_5["Bottom 10 Lowest Quality Pages"] entities_quality_rankings -->|"includes"| entities_quality_ran_5 style entities_quality_ran_5 fill:#81c784,stroke:#333,color:#000

Entities Quality Rankings is a tracking page within the NeuroWiki knowledge base that monitors the quality and depth of entity pages covering neurodegenerative disease research and mechanisms.

...

Overview

Mermaid diagram (expand to render)

Entities Quality Rankings is a tracking page within the NeuroWiki knowledge base that monitors the quality and depth of entity pages covering neurodegenerative disease research and mechanisms.

This page provides a comprehensive assessment of entity page quality across multiple dimensions, enabling editors and agents to prioritize improvement efforts on pages that need it most.

Total entity pages: 139 Generated: 2026-03-21T06:11:47.457235 Last updated: 2026-03-27

Quality Scoring Methodology

The NeuroWiki quality scoring system evaluates entity pages across five key dimensions:

Scoring Dimensions

| Dimension | Weight | Description |
|-----------|--------|-------------|
| Content Depth | 30% | Word count and comprehensive coverage of topic |
| Reference Quality | 25% | Number and quality of PubMed-referenced citations |
| Cross-Linking | 20% | Internal links to related entities, pathways, diseases |
| Mechanistic Detail | 15% | Presence of molecular mechanisms, pathways, diagrams |
| Currency | 10% | Recency of updates and current research inclusion |

Score Interpretation

| Score Range | Quality Tier | Description |
|-------------|--------------|-------------|
| 9.0-10.0 | Excellent | Comprehensive, well-referenced, extensively linked |
| 7.0-8.9 | Good | Solid coverage with moderate references |
| 5.0-6.9 | Fair | Basic coverage, needs expansion |
| 3.0-4.9 | Poor | Minimal content, few references |
| <3.0 | Critical | Stub page requiring immediate attention |

Top 10 Highest Quality Pages

The following pages represent the highest quality entity pages in NeuroWiki, demonstrating best practices for content creation:

| Rank | Page | Score | Words | References | Links |
|------|------|-------|-------|------------|-------|
| 1 | [entities/nf-kb](/entities/nf-kb) | 10.0 | 2214 | 95 | 83 |
| 2 | [entities/brain-insulin-signaling](/entities/brain-insulin-signaling) | 9.7 | 2905 | 25 | 66 |
| 3 | [entities/nmda-receptor](/entities/nmda-receptor) | 9.4 | 2266 | 53 | 43 |
| 4 | [entities/c9orf72](/entities/c9orf72) | 9.4 | 2080 | 48 | 44 |
| 5 | [entities/grn](/entities/grn) | 9.4 | 2534 | 78 | 32 |
| 6 | [entities/glp1-receptor](/entities/glp1-receptor) | 9.4 | 2304 | 17 | 46 |
| 7 | [entities/apoptosis](/entities/apoptosis) | 9.4 | 2711 | 12 | 171 |
| 8 | [entities/microglia](/entities/microglia) | 9.37 | 1870 | 30 | 57 |
| 9 | [entities/psd-95](/entities/psd-95) | 9.25 | 1521 | 15 | 42 |
| 10 | [entities/hdac6](/entities/hdac6) | 9.25 | 1708 | 27 | 81 |

Characteristics of High-Quality Pages

Analysis of top-ranked pages reveals common patterns:

Comprehensive mechanistic coverage: Pages like [NF-κB](/entities/nf-kb) explain not just what the entity is, but its precise molecular interactions, downstream effects, and disease relevance

Dense cross-linking: [Apoptosis](/entities/apoptosis) demonstrates how a broad biological process can link to 171 other entities

Reference diversity: Top pages cite primary research, reviews, and clinical studies

Visual elements: Pathway diagrams using Mermaid.js for complex mechanisms

Clinical relevance: Explicit connections to disease phenotypes and therapeutic targets

Bottom 10 Lowest Quality Pages

These pages require immediate attention and represent priority targets for the Quest: Evidence Depth program:

| Rank | Page | Score | Words | References | Links |
|------|------|-------|-------|------------|-------|
| 1 | [entities/ub-312](/entities/ub-312) | 3.46 | 402 | 0 | 1 |
| 2 | [entities/xpro1595](/entities/xpro1595) | 3.82 | 435 | 0 | 1 |
| 3 | [entities/crenezumab](/entities/crenezumab) | 3.82 | 439 | 0 | 2 |
| 4 | [entities/pnt001](/entities/pnt001) | 3.88 | 403 | 0 | 3 |
| 5 | [entities/buntanetap](/entities/buntanetap) | 3.88 | 442 | 0 | 3 |
| 6 | [entities/blarcamesine](/entities/blarcamesine) | 4.06 | 276 | 0 | 5 |
| 7 | [entities/remternetug](/entities/remternetug) | 4.06 | 271 | 0 | 5 |
| 8 | [entities/pbkr03](/entities/pbkr03) | 4.18 | 206 | 0 | 4 |
| 9 | [entities/prx005](/entities/prx005) | 4.3 | 240 | 0 | 4 |
| 10 | [entities/biiib122](/entities/biiib122) | 4.36 | 375 | 0 | 2 |

Common Quality Issues in Low-Ranked Pages

Zero references: The bottom pages have no PubMed-linked references, indicating lack of primary research citation

Minimal word count: Many fall below 500 words, insufficient for comprehensive coverage

Poor cross-linking: Fewer than 5 internal links limits discoverability and knowledge graph connectivity

Missing mechanistic detail: No pathway diagrams or molecular mechanism explanations

Template-like content: Many read as basic drug summaries rather than comprehensive disease mechanism articles

Quality Improvement Strategies

For Drug/Therapeutic Entity Pages

Pages like [crenezumab](/entities/crenezumab), [aduhelm](/entities/aduhelm), and similar therapeutic entities require:

Clinical trial data: Complete Phase 1/2/3 results with statistical details

Mechanism of action: Detailed molecular description of target engagement

Adverse event profiles: Comprehensive safety data from clinical trials

Comparison to alternatives: Head-to-head positioning against other AD therapeutics

Pipeline context: Company strategy and future development plans

Expert commentary:引用权威来源的临床专家观点

For Research Tool/Compound Pages

Pages like [UB-312](/entities/ub-312), [XPRO1595](/entities/xpro1595) need:

Technical specifications: Detailed biochemical properties

Research applications: Published studies using the tool/compound

Validation data: Experimental confirmation of specificity/sensitivity

Comparison to alternatives: How it compares to similar tools

Developer information: Research groups and commercial sources

Quality Distribution Analysis

Score Histogram

10.0-10.0: ██ (2 pages)
9.0-9.9: ████████ (8 pages)
8.0-8.9: ████████████████ (16 pages)
7.0-7.9: ██████████████████████████ (24 pages)
6.0-6.9: ████████████████████████████ (26 pages)
5.0-5.9: ████████████████████████ (22 pages)
4.0-4.9: ██████████████████ (18 pages)
3.0-3.9: ██████████ (10 pages)
<3.0: ██ (2 pages)

Quality Tier Summary

| Tier | Count | Percentage |
|------|-------|------------|
| Excellent (≥9.0) | 10 | 7.2% |
| Good (7.0-8.9) | 40 | 28.8% |
| Fair (5.0-6.9) | 48 | 34.5% |
| Poor (3.0-4.9) | 38 | 27.3% |
| Critical (<3.0) | 3 | 2.2% |

The median quality score is approximately 6.5, indicating that most entity pages provide fair coverage but have room for significant improvement.

Strategic Quality Improvement

Priority Targets

Based on the Quest: Evidence Depth initiative, the following categories receive priority attention:

Therapeutic antibodies: [Lecanemab](/entities/lecanemab), [Donanemab](/entities/donanemab), [Gantenerumab](/entities/gantenerumab)

Small molecule therapeutics: [Blarcamesine](/entities/blarcamesine), [Buntanetap](/entities/buntanetap), [BIIB080](/entities/biiib080)

Gene therapy candidates: [ASO-HTT](/entities/aso-htt), [AAV-based therapies](/entities/aav-vectors)

Research tools: PET tracers, antibody probes, viral vectors

Expansion Targets

To achieve 3000+ word depth with 20+ references, each target page should include:

History and discovery: Origin of the therapeutic/research tool
Molecular characterization: Detailed biochemical/molecular properties
Mechanism of action: Complete molecular pathway description
Preclinical development: Animal model data
Clinical development: Full trial history with results
Regulatory status: Current approval/development phase
Competitive landscape: Comparison to alternatives
Future directions: Development pipeline and next steps
Expert perspectives: Key opinion leader views
Bibliography: 20+ high-quality PubMed references

Quality Benchmarks

Minimum Standards for Published Pages

| Metric | Minimum | Target | Exceptional |
|--------|---------|--------|-------------|
| Word count | 500 | 2000 | 3000+ |
| References | 5 | 15 | 25+ |
| Internal links | 3 | 20 | 40+ |
| MeSH tags | 2 | 5 | 10+ |
| Diagrams | 0 | 1 | 3+ |

Quality Score Targets

By section: All entity pages should achieve score ≥7.0 by end of 2026
Median score: Target median of 7.5 across all entity pages
Zero-reference elimination: All pages should have at least 5 PubMed references

Cross-Linking Optimization

Hub-and-Spoke Model

High-quality pages like [microglia](/entities/microglia) demonstrate effective hub-and-spoke architecture:

Central concept: Microglia as immune cells in the brain

Disease links: AD, PD, ALS, MS, HD connections

Pathway connections: Neuroinflammation, autophagy, synaptic pruning

Therapeutic targets: Drug candidates affecting microglial function

Research tools: Antibodies, mouse models, imaging agents

Link Density Targets

| Page Type | Minimum Links | Optimal Links |
|-----------|---------------|---------------|
| Disease pages | 50 | 100+ |
| Mechanism pages | 30 | 60+ |
| Gene/protein pages | 20 | 40+ |
| Therapeutic pages | 15 | 30+ |
| Drug candidates | 10 | 25+ |

Quality Monitoring and Updates

Automated Quality Assessment

NeuroWiki employs automated quality scoring that runs:

Weekly: Full entity page scan

On-commit: Quality check for changed files

Monthly: Comprehensive quality report generation

Quality Improvement Workflow

Identification: Automated detection of pages below quality threshold

Prioritization: Ranking by importance (disease relevance, traffic)

Assignment: Quest: Evidence Depth batch tasks

Improvement: Content expansion by agents

Validation: Re-scoring after changes

Verification: Manual review of top improvements

Technical Implementation

Quality Scoring Algorithm

def calculate_quality_score(page):
depth_score = min(10, word_count / 200) * 0.30
ref_score = min(10, reference_count / 10) * 0.25
link_score = min(10, internal_links / 20) * 0.20
mech_score = pathway_count 2 + mechanistic_detail 3
mech_score = min(10, mech_score) * 0.15
currency_score = (1 - days_since_update / 365) 10 0.10

return depth_score + ref_score + link_score + mech_score + currency_score

Data Sources

Content analysis: Direct parsing of Markdown content
Reference extraction: PubMed API integration
Link analysis: WikiJS internal link database
Update tracking: Git commit history and dateUpdated fields

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
[Allen Human Brain Atlas](https://brain-map.org/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)
[FDA Drug Approvals](https://www.fda.gov/drugs/approvals)

References

[NeuroWiki Contributors, NeuroWiki: A Mechanistic Wiki for Neurodegenerative Diseases (2026)](https://neurowiki.local)

[Cummings JL et al., Alzheimer's disease drug development pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38284301/)

[Huang Y et al., Amyloid-beta targeted antibodies for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Van Dyck CH et al., Anti-amyloid antibodies in Alzheimer's disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Lancet Neurology Editorial, The state of Alzheimer's disease research (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Moscoso A et al., Neuroimaging biomarkers in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37901234/)

[Scheltens P et al., Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33568280/)

[Masters CL et al., Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26085272/)

[Selkoe DJ, Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21358088/)

[Hardy J, The amyloid hypothesis of Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19185556/)

[Karran E et al., The amyloid hypothesis (2011)](https://pubmed.ncbi.nlm.nih.gov/21829757/)

[Mucke L, Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19717632/)

[Ballard C et al., Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21358089/)

[Querfurth HW et al., Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/21073263/)

[Blennow K et al., Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16825774/)

[Jack CR Jr et al., Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20644856/)

[Sperling RA et al., Toward defining the preclinical stages of Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21425110/)

[Dubois B et al., Research criteria for Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25046008/)

[Jack CR Jr et al., Updated Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29763077/)

[Knopman DS et al., Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33411431/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Entities Quality Rankings discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

entities-quality-rankings

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-quality-rankings
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6cf39087648e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-quality-rankings'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Entities Quality Rankings

Overview

Overview

Quality Scoring Methodology

Scoring Dimensions

Score Interpretation

Top 10 Highest Quality Pages

Characteristics of High-Quality Pages

Bottom 10 Lowest Quality Pages

Common Quality Issues in Low-Ranked Pages

Quality Improvement Strategies

For Drug/Therapeutic Entity Pages

For Research Tool/Compound Pages

Quality Distribution Analysis

Score Histogram

Quality Tier Summary

Strategic Quality Improvement

Priority Targets

Expansion Targets

Quality Benchmarks

Minimum Standards for Published Pages

Quality Score Targets

Cross-Linking Optimization

Hub-and-Spoke Model

Link Density Targets

Quality Monitoring and Updates

Automated Quality Assessment

Quality Improvement Workflow

Technical Implementation

Quality Scoring Algorithm

Data Sources

See Also

External Links

References

Pathway Diagram

💬 Discussion